Skip to main content
SpringerLink
Log in
Book cover

Signaling Pathways in Liver Diseases pp 275–285Cite as

AMP-Activated Protein Kinase in Liver

  • Chapter
  • First Online:

  • 1534 Accesses

Abstract

The AMP-activated protein kinase (AMPK) has become an inescapable topic in metabolic disorders. AMPK is a highly conserved eukaryotic protein serine/threonine kinase, which is involved in energy homeostasis both at the cellular and whole-body levels [1–3]. It mediates a nutrient signaling pathway that senses the energy status of the cell and is activated by energy imbalance as a result of decreased ATP production (hypoxia) or increased ATP consumption (muscle contraction). Liver AMPK activity is also modulated by cytokines that regulates whole-body energy homeostasis. At the cellular level, AMPK restores energy charge by switching off anabolic ATP-consuming pathways, while switching on catabolic ATP-generating pathways. It also plays a critical role in systemic energy homeostasis by controlling food intake in the hypothalamus [1–3]. Therefore, AMPK orchestrates a global metabolic response to energy deprivation and can be regarded as a starvation signal. This short article reviews the conditions and consequences of AMPK activation in liver and the potential implication of AMPK in liver diseases.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8:774–785

    Article  PubMed  CAS  Google Scholar 

  2. Hardie DG, Carling D, Carlson M (1998) The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 67:821–855

    Article  PubMed  CAS  Google Scholar 

  3. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15–25

    Article  PubMed  CAS  Google Scholar 

  4. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D (2000) Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 346:659–669

    Article  PubMed  CAS  Google Scholar 

  5. Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C, Walker PA, Haire L, Eccleston JF, Davis CT, Martin SR, Carling D, Gamblin SJ (2007) Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 449:496–500

    Article  PubMed  CAS  Google Scholar 

  6. Witters LA, Kemp BE, Means AR (2006) Chutes and Ladders: the search for protein kinases that act on AMPK. Trends Biochem Sci 31:13–16

    Article  PubMed  CAS  Google Scholar 

  7. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 403:139–148

    Article  PubMed  CAS  Google Scholar 

  8. Hue L, Rider MH (2007) The AMP-activated protein kinase: more than an energy sensor. Essays Biochem 43:121–137

    Article  PubMed  CAS  Google Scholar 

  9. Momcilovic M, Hong SP, Carlson M (2006) Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 281:25336–25343

    Article  PubMed  CAS  Google Scholar 

  10. Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der Smissen P, Dietz HC, Courtoy PJ, Rousseau GG, Lemaigre FP (2005) Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors. Genes Dev 19:1849–1854

    Article  PubMed  CAS  Google Scholar 

  11. Hardie DG (2007) AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 47:185–210

    Article  PubMed  CAS  Google Scholar 

  12. Winder WW, Hardie DG (1996) Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 270:E299–E304

    Google Scholar 

  13. Assifi MM, Suchankova G, Constant S, Prentki M, Saha AK, Ruderman NB (2005) AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab 289:E794–E800

    Article  CAS  Google Scholar 

  14. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295

    Article  PubMed  CAS  Google Scholar 

  15. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK, Ruderman NB (2004) AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320:449–454

    Article  PubMed  CAS  Google Scholar 

  16. Corton JM, Gillespie JG, Hawley SA, Hardie DG (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558–565

    Article  PubMed  CAS  Google Scholar 

  17. Henin N, Vincent MF, Gruber HE, Van den Berghe G (1995) Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 9:541–546

    PubMed  CAS  Google Scholar 

  18. Reiter AK, Bolster DR, Crozier SJ, Kimball SR, Jefferson LS (2005) Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator ­aminoimidazole carboxamide ribonucleoside. Am J Physiol Endocrinol Metab 288:E980–E988

    Article  CAS  Google Scholar 

  19. Guigas B, Bertrand L, Taleux N, Foretz M, Wiernsperger N, Vertommen D, Andreelli F, Viollet B, Hue L (2006) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes 55:865–874

    Article  PubMed  CAS  Google Scholar 

  20. Guigas B, Taleux N, Foretz M, Detaille D, Andreelli F, Viollet B, Hue L (2007) AMP-activated protein kinase-­independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Biochem J 404:499–507

    Article  PubMed  CAS  Google Scholar 

  21. Guigas B, Sakamato K, Taleux N, Reyna SM, Musi N, Viollet B, Hue L (2009) Beyond AICA riboside: In search of new specific AMP-activated protein kinase activators. IUBMB Life 61:18–26

    Google Scholar 

  22. Pencek RR, Shearer J, Camacho RC, James FD, Lacy DB, Fueger PT, Donahue EP, Snead W, Wasserman DH (2005) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside causes acute hepatic insulin resistance in vivo. Diabetes 54:355–360

    Article  PubMed  CAS  Google Scholar 

  23. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, Zhao G, Marsh K, Kym P, Jung P, Camp HS, Frevert E (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3:403–416

    Article  PubMed  CAS  Google Scholar 

  24. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282:32539–32548

    Article  PubMed  CAS  Google Scholar 

  25. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223–228

    Article  PubMed  CAS  Google Scholar 

  26. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607–614

    Article  PubMed  CAS  Google Scholar 

  27. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174

    PubMed  CAS  Google Scholar 

  28. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510–515

    Article  PubMed  CAS  Google Scholar 

  29. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273–280

    Article  PubMed  CAS  Google Scholar 

  30. Alnouti Y, Petrick JS, Klaassen CD (2006) Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab Dispos 34:477–482

    PubMed  CAS  Google Scholar 

  31. Inoue Y, Kurihara R, Tsuchida A, Hasegawa M, Nagashima T, Mori T, Niidome T, Katayama Y, Okitsu O (2008) Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. J Control Release 126:159–166

    Article  CAS  Google Scholar 

  32. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, Furnsinn C (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052–1059

    Article  PubMed  CAS  Google Scholar 

  33. Fryer LG, Parbu-Patel A, Carling D (2002) The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226–25232

    Article  PubMed  CAS  Google Scholar 

  34. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, Tomas E (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 291:E175–E181

    Article  CAS  Google Scholar 

  35. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB (2004) Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314:580–585

    Article  PubMed  CAS  Google Scholar 

  36. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281:2654–2660

    Article  PubMed  CAS  Google Scholar 

  37. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305:390–392

    Article  PubMed  CAS  Google Scholar 

  38. Lan F, Cacicedo JM, Ruderman N, Ido Y (2008) SIRT1 Modulation of the acetylation status, cytosolic localization, and activity of lkb1: possible role in AMP-activated protein kinase activation. J Biol Chem 283:27628–27635

    Article  PubMed  CAS  Google Scholar 

  39. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, Cohen RA, Zang M (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283:20015–20026

    Article  PubMed  CAS  Google Scholar 

  40. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113–118

    Article  PubMed  CAS  Google Scholar 

  41. Hardie DG, Hawley SA, Scott JW (2006) AMP-activated protein kinase – development of the energy sensor concept. J Physiol 574:7–15

    Article  PubMed  CAS  Google Scholar 

  42. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R, Bertrand L (2009) AMPK: lessons from transgenic and knockout animals. Front Biosci 14:19–44

    Article  PubMed  CAS  Google Scholar 

  43. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, Hue L, Andreelli F (2006) Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 574:41–53

    Article  PubMed  CAS  Google Scholar 

  44. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, Pillot B, Bado A, Tronche F, Mithieux G, Vaulont S, Burcelin R, Viollet B (2006) Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147:2432–2441

    Article  PubMed  CAS  Google Scholar 

  45. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR 3rd, Young LH, Shulman GI (2001) Effect of 5-­aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50:1076–1082

    Article  PubMed  CAS  Google Scholar 

  46. Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, Vaulont S, Viollet B (2005) Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54:1331–1339

    Article  PubMed  CAS  Google Scholar 

  47. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642–1646

    Article  PubMed  CAS  Google Scholar 

  48. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG, Alessi DR (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23:833–843

    Article  PubMed  CAS  Google Scholar 

  49. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P, Takemori H, Montminy M (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437:1109–1111

    Article  PubMed  CAS  Google Scholar 

  50. Hong YH, Varanasi US, Yang W, Leff T (2003) AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. J Biol Chem 278:27495–27501

    Article  PubMed  CAS  Google Scholar 

  51. Leclerc I, Lenzner C, Gourdon L, Vaulont S, Kahn A, Viollet B (2001) Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes 50:1515–1521

    Article  PubMed  CAS  Google Scholar 

  52. Foretz M, Carling D, Guichard C, Ferre P, Foufelle F (1998) AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem 273:14767–14771

    Article  PubMed  CAS  Google Scholar 

  53. Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F, Carling D (2000) Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 20:6704–6711

    Article  PubMed  CAS  Google Scholar 

  54. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F (2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86:839–848

    Article  PubMed  CAS  Google Scholar 

  55. Ferre P, Azzout-Marniche D, Foufelle F (2003) AMP-activated protein kinase and hepatic genes involved in glucose metabolism. Biochem Soc Trans 31:220–223

    Article  PubMed  CAS  Google Scholar 

  56. Postic C, Dentin R, Denechaud PD, Girard J (2007) ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu Rev Nutr 27:179–192

    Article  PubMed  CAS  Google Scholar 

  57. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118:829–838

    Article  PubMed  CAS  Google Scholar 

  58. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T, Uyeda K (2002) Mechanism for fatty acid “sparing” effect on glucose-induced transcription: regulation of ­carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 277:3829–3835

    Article  PubMed  CAS  Google Scholar 

  59. Jensen TE, Schjerling P, Viollet B, Wojtaszewski JF, Richter EA (2008) AMPK alpha1 activation is required for stimulation of glucose uptake by twitch contraction, but not by H2O2, in mouse skeletal muscle. PLoS ONE 3:e2102

    Article  CAS  Google Scholar 

  60. Jorgensen SB, Richter EA, Wojtaszewski JF (2006) Role of AMPK in skeletal muscle metabolic regulation and adaptation in relation to exercise. J Physiol 574:17–31

    Article  PubMed  CAS  Google Scholar 

  61. Carling D, Hardie DG (1989) The substrate and sequence specificity of the AMP-activated protein kinase. Phos­phorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta 1012:81–86

    Article  PubMed  CAS  Google Scholar 

  62. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S (2003) The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 111: 91–98

    PubMed  CAS  Google Scholar 

  63. Ferre P, Foufelle F (2007) SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 68:72–82

    PubMed  CAS  Google Scholar 

  64. Jager S, Handschin C, St-Pierre J, Spiegelman BM (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 104:12017–12022

    Article  PubMed  CAS  Google Scholar 

  65. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, Motoshima H, Taguchi T, Matsumura T, Araki E (2006) Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55:120–127

    Article  PubMed  CAS  Google Scholar 

  66. Reznick RM, Zong H, Li J, Morino K, Moore IK, Yu HJ, Liu ZX, Dong J, Mustard KJ, Hawley SA, Befroy D, Pypaert M, Hardie DG, Young LH, Shulman GI (2007) Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab 5:151–156

    Article  PubMed  CAS  Google Scholar 

  67. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A 99:15983–15987

    Article  PubMed  CAS  Google Scholar 

  68. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342

    Article  PubMed  CAS  Google Scholar 

  69. Proud CG (2007) Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 403:217–234

    Article  PubMed  CAS  Google Scholar 

  70. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590

    Article  PubMed  CAS  Google Scholar 

  71. Cheng SW, Fryer LG, Carling D, Shepherd PR (2004) Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 279:15719–15722

    Article  PubMed  CAS  Google Scholar 

  72. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214–226

    Article  PubMed  CAS  Google Scholar 

  73. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoinne A, Hue L, Proud C, Rider M (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12:1419–1423

    Article  PubMed  CAS  Google Scholar 

  74. Krause U, Bertrand L, Hue L (2002) Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem 269:3751–3759

    Article  PubMed  CAS  Google Scholar 

  75. Motoshima H, Goldstein BJ, Igata M, Araki E (2006) AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574:63–71

    Article  PubMed  CAS  Google Scholar 

  76. Rattan R, Giri S, Singh AK, Singh I (2005) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280:39582–39593

    Article  PubMed  CAS  Google Scholar 

  77. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745–6752

    Article  PubMed  CAS  Google Scholar 

  78. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18:283–293

    Article  PubMed  CAS  Google Scholar 

  79. Meisse D, Van de Casteele M, Beauloye C, Hainault I, Kefas BA, Rider MH, Foufelle F, Hue L (2002) Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 526:38–42

    Article  PubMed  CAS  Google Scholar 

  80. Blume C, Benz PM, Walter U, Ha J, Kemp BE, Renne T (2007) AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein. J Biol Chem 282:4601–4612

    Article  PubMed  CAS  Google Scholar 

  81. Zhang L, Li J, Young LH, Caplan MJ (2006) AMP-activated protein kinase regulates the assembly of epithelial tight junctions. Proc Natl Acad Sci U S A 103:17272–17277

    Article  PubMed  CAS  Google Scholar 

  82. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792

    Article  PubMed  CAS  Google Scholar 

  83. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB (2006) Adiponectin – a key adipokine in the metabolic syndrome. Diabetes Obes Metab 8:264–280

    Article  PubMed  CAS  Google Scholar 

  84. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–25866

    Article  PubMed  CAS  Google Scholar 

  85. Ma K, Cabrero A, Saha PK, Kojima H, Li L, Chang BH, Paul A, Chan L (2002) Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 277:34658–34661

    Article  PubMed  CAS  Google Scholar 

  86. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731–737

    Article  PubMed  CAS  Google Scholar 

  87. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332–339

    Article  PubMed  CAS  Google Scholar 

  88. Aguilera CM, Gil-Campos M, Canete R, Gil A (2008) Alterations in plasma and tissue lipids associated with ­obesity and metabolic syndrome. Clin Sci (Lond) 114:183–193

    Article  CAS  Google Scholar 

  89. Dixon JB, Bhathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100

    Article  PubMed  CAS  Google Scholar 

  90. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850

    Article  PubMed  CAS  Google Scholar 

  91. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364–1370

    Article  PubMed  CAS  Google Scholar 

  92. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998–1003

    Article  PubMed  CAS  Google Scholar 

  93. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroentero­logy 135:100–110

    Article  PubMed  CAS  Google Scholar 

  94. Rogers CQ, Ajmo JM, You M (2008) Adiponectin and alcoholic fatty liver disease. IUBMB Life 60:790–797

    Google Scholar 

  95. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91–100

    PubMed  CAS  Google Scholar 

  96. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW (2004) The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127:1798–1808

    Article  PubMed  CAS  Google Scholar 

  97. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M (2008) Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 295:G833–G842

    Article  CAS  Google Scholar 

  98. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H (2001) Cell cycle regulation via p53 phosphorylation by a 5’-AMP activated protein kinase activator, 5-aminoimidazole-­4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287:562–567

    Article  PubMed  CAS  Google Scholar 

  99. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305

    Article  PubMed  Google Scholar 

  100. Fasolo A, Sessa C (2008) mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 17:1717–1734

    Article  PubMed  CAS  Google Scholar 

  101. Semela D, Piguet A-C, Kolev M, Schmitter K, Hlushchuk R, Djonov V, Stoupis C, Dufour J-F (2007) Vascular remodeling and atitumoral effects of mTOR inhibition in a rat model of hepatocelluar carcinoma. J Hepatol 46:840–848

    Article  PubMed  CAS  Google Scholar 

  102. Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379–1406

    Article  PubMed  CAS  Google Scholar 

  103. Guigas B, Hue L (2008) Metformin and the AMP activated protein kinase. In: Mitieux G, Wiernsperger N (eds) Metformin: mechanistic insights towards new applications. Transworld Research Network:Chap 5, pp 81–110

    Google Scholar 

Download references

Acknowledgments

The work carried out in the authors’ laboratory was supported by the Belgian Fund for Medical Scien­tific Research, the Interuniversity Poles of Attraction Belgian Science Policy , the French Community of Belgium (Actions de Recherche Concertées) and the EXGENESIS Integrated Project (LSHM-CT-2004-005272) from the European Commission.

Author information

Authors and Affiliations

  1. Hormone and Metabolic Research Unit, Université catholique de Louvain, and de Duve Institute Avenue, Hippocrate, 75, UCL 7529, B-1200, Brussels, Belgium

    Louis Hue, Laurent Bultot & Mark H. Rider

Authors
  1. Louis Hue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurent Bultot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark H. Rider
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louis Hue .

Editor information

Editors and Affiliations

  1. Inselspital, Universität Bern, Murtenstr. 35, Bern, 3010, Switzerland

    Jean-Francois Dufour

  2. Klinik für Viszeral- und, Universitätsspital Zürich, Rämistr. 100, Zürich, 8091, Switzerland

    Pierre-Alain Clavien

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hue, L., Bultot, L., Rider, M.H. (2010). AMP-Activated Protein Kinase in Liver. In: Dufour, JF., Clavien, PA. (eds) Signaling Pathways in Liver Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00150-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-00150-5_18

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-00149-9

  • Online ISBN: 978-3-642-00150-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation